Women's health spans contraception (IUDs, implants), endometrial ablation, fibroid treatment, pelvic floor and incontinence devices, breast biopsy and imaging (Hologic), and fetal/maternal monitoring. The segment covers fertility, contraception, pregnancy monitoring, menopause, breast health and pelvic floor devices. Some products, such as transvaginal mesh, have faced heavy FDA safety actions. Investment has grown, but clinical evidence and payment can be hard to secure.

Why it matters

Historically underfunded; FemTech investment surged post-2020. Reimbursement and patient pay-mix vary dramatically by sub-segment.

Common pitfalls

•A common pitfall is failing to account for sex-specific physiological differences in device design and clinical trial enrollment, potentially leading to suboptimal efficacy or safety for women.
•Another mistake is overlooking the unique cybersecurity and privacy considerations for sensitive health data related to reproductive health or personal wellness devices.
•Companies sometimes misinterpret reimbursement codes, leading to commercialization delays or market access issues.
•Inaccurate labeling or promotional claims that overstate benefits specific to women's health can lead to regulatory scrutiny and enforcement actions.

Sources

ACOG · ACOG
AdvaMed - Industry Reports · AdvaMed
MedTech Europe - Facts & Figures · MedTech Europe
Breast Implants · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.